Impact of vitamin D supplementation on cardio-metabolic status and androgen profile in women with polycystic ovary syndrome: placebo-controlled clinical trial

Rashad, Nearmeen M.; Abd El-Fatah, Azza H.; Lashin, Mohamed El-Bakry; Abomandour, Hala G.; Allam, Reem M.

doi:10.1186/s43043-019-0005-y

Middle East Fertility Society Journal

Table 1 Clinical and biochemical characteristics of the studied groups

From: Impact of vitamin D supplementation on cardio-metabolic status and androgen profile in women with polycystic ovary syndrome: placebo-controlled clinical trial

	Control group (mean ± SD) (n = 50)	PCO patients (mean ± SD) (n = 95)	P
Age (years)	27.98 ± 6.11	26.05 ± 3.72	0.085
BMI (kg/m2)	26.79 ± 2.84	27.99 ± 5.772	0.564
Waist/hip ratio	0.91 ± 0.103	1.49 ± 0.321	˂ 0.001^*
Systolic blood pressure (mmHg)	117.96 ± 6.85	125.9 ± 5.89	˂ 0.001^*
Diastolic blood pressure (mmHg)	72.74 ± 8.05	89.18 ± 3.82	˂ 0.001^*
Hirsutism score	5.54 ± 0.54	8.35 ± 5.81	˂ 0.001^*
Ovarian volume	7.43 ± 1.41	15.41 ± 4.147	˂ 0.001^*
AFC	5.42 ± 0.92	14.91 ± 5.147	˂ 0.001^*
T.cholesterol (mg/dL)	158.8 ± 14.6	202.35 ± 31.73	˂ 0.001^*
Triglycerides (mg/dL)	143.2 ± 23.04	194.8 ± 46.02	˂ 0.001^*
LDL.C(mg/dL)	76.5 ± 13.84	120.39 ± 31.04	˂ 0.001^*
HDL.C(mg/dL)	53.7 ± 3.26	42.9 ± 6.22	˂ 0.001^*
FPG (mg/dL)	85.2 ± 8.02	87.96 ± 3.5	˂ 0.001^*
FSI (μU/mL)	6.2 ± 1.75	11.26 ± 6.2	˂ 0.001^*
HOMA-IR	1.2 ± 0.23	2.45 ± 1.36	˂ 0.001^*
HOMA β	172.2 ± 117.6	199.19 ± 57.57	˂ 0.001^*
Total testosterone (ng/mL)	0.56 ± 0.16	0.784 ± 0.36	˂ 0.001^*
Free testosterone (pg/mL)	0.998 ± 0.347	2.43 ± 1.21	˂ 0.001^*
SHBG (nmol/L)	88.95 ± 11.9	36.89 ± 18.63	˂ 0.001^*
DHEA-S (μg/dl))	162.44 ± 26.54	212.45 ± 81.15	˂ 0.001^*
Androstenedione (ng/mL)	1.19 ± 0.36	2.86 ± 1.93	˂ 0.001^*
FSH (mIU/mL)	6.84 ± 2.044	8.59 ± 0.467	˂ 0.001^*
LH (mIU/mL)	8.21 ± 0.54	10.57 ± 2.41	˂ 0.001^*
LH/FSH	1.06 ± 0.15	1.14 ± 0.122	˂ 0.001^*
25(OH)-D (ng/ml)	39.54 ± 8.13	14.27 ± 4.48	˂ 0.001^*
Ca (mg/dl)	9.20 ± 0.97	8.22 ± 0.89	˂ 0.001^*
PO4 (mg/dl)	4.29 ± 0.83	5.48 ± 0.597	˂ 0.001^*
Albumin (g/dl)	3.99 ± 0.15	4.26 ± 0.637	˂ 0.001^*
Alkaline phosphatase (IU/L)	105.6 ± 17.3	127.67 ± 30.3	˂ 0.001^*
WBC count (cell × 103/μl)	4.96 ± 1.83	7.94 ± 1.766	˂ 0.001^*
Neutrophil count (cell × 10³/μl)	2.71 ± 0.66	3.79 ± 1.09	˂ 0.001^*
hs-CRP (μg/ml)	2.29 ± 0.38	4.976 ± 0.952	˂ 0.001^*
CIMT(mm)	0.77 ± 0.186	1.44 ± 0.22	˂ 0.001^*

BMI body mass index, AFC antral follicle count, FSI fasting serum insulin, FPG fasting plasma glucose, HOMA-IR homeostasis model assessments of insulin resistance, SHBG sex hormone-binding globulin, DHEA-S dehydroepiandrosteron sulfate, ALP alkaline phosphatase, hs-CRP high-sensitivity C-reactive protein, CIMT carotid intima-media thickness
*P < 0.05 when compared with control group

Back to article page